Skip to main content
Fig. 4 | Respiratory Research

Fig. 4

From: Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma

Fig. 4

Difference versus placebo at 3 weeks of adjusted mean FEV1 AUC0–12 (a) and AUC12–24 (b). FEV1: forced expiratory volume in 1 s; AUC0–12: area under the curve from 0 to 12 h; SE: standard error; BID: twice daily; QD: once daily; AUC12–24: area under the curve from 12 to 24 h

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us